Stomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others), By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors), By Route of Administration (Oral v/s Injectables), By Drug Class (PD-1/PD-L1 Inhibito
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationStomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others), By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors), By Route of Administration (Oral v/s Injectables), By Drug Class (PD-1/PD-L1 Inhibito
The global stomach cancer treatment market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenario for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, growing aging population across the globe which is more prone to different kinds of chronic diseases like stomach cancer is further expected to increase the demand for different cancer therapies, thereby fuelling the market growth through 2028. Besides, growing awareness about the benefits of new therapies, with increasing expenditure on cancer diseases worldwide is further expected to support the stomach cancer treatment market during the forecast period. Surgery is often the first line of treatment for stomach cancer, particularly for early-stage disease. During surgery, the tumor and surrounding tissue are removed, which can help to prevent the cancer from spreading to other parts of the body. In some cases, the entire stomach may need to be removed, a procedure known as a gastrectomy. While surgery can be highly effective for early-stage stomach cancer, it may be less effective for more advanced disease. The cost of stomach cancer treatment can be very high, particularly for advanced treatments such as targeted therapy and immunotherapy. This can be a barrier to accessing treatment for many patients, particularly in developing countries. Stomach cancer treatment can be associated with a number of side effects, which can impact patients' quality of life. This can make it difficult for patients to continue with their treatment regimen and can reduce the effectiveness of treatment. Despite the high prevalence of stomach cancer, there is still a lack of awareness about the disease and its treatment options. This can lead to delays in diagnosis and treatment, which can impact patients' outcomes. Like many other types of cancer, stomach cancer can develop resistance to certain treatments over time. This can make it difficult to achieve long-term remission and can limit the effectiveness of treatment options. While advanced treatments such as targeted therapy and immunotherapy are found at for stomach cancer, they may not be widely found at in all regions. This can limit patients' access to the most effective treatments and can impact the growth of the market.
Growing Prevalence of Stomach Cancer
According to National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States.
Growing Development in Healthcare Industry
For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers.
Recent Development
- For instance, in April 2021, the U.S. FDA approved Bristol-Myers Squibb Company’s product Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of metastatic gastric cancer.
- Enhertu is a targeted therapy that was approved by the US FDA in 2019 for the treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The drug is a combination of an antibody and a chemotherapy agent, and targets the HER2 protein that is overexpressed in some types of stomach cancer. In clinical trials, Enhertu has shown promising results in improving overall survival and reducing the risk of disease progression.
- Tukysa is another targeted therapy that was approved by the US FDA in 2020 for the treatment of HER2-positive advanced or metastatic gastric or GEJ adenocarcinoma. Like Enhertu, Tukysa targets the HER2 protein, but works by blocking the activity of enzymes that promote cancer growth. In clinical trials, Tukysa has been shown to improve progression-free survival and overall survival compared to standard chemotherapy.
Market Segmentation
The global stomach cancer treatment market can be segmented by treatment type, by cancer type, by route of administration, by drug class, by distribution channel and by region. Based on treatment type, the market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others. Based on cancer type, the market can be differentiated into Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors. Based on route of administration, the market can be divided into Oral v/s Injectables. Based on drug class, the market can be segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others. Based on distribution channel, the market can be grouped into Hospital Pharmacies, Specialty Pharmacies, Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global stomach cancer treatment market on account of growing demand for advance cancer therapy in the country.
Market Players
Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.
Download Sample Report
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy